{{medical}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 458476745
| IUPAC_name = (''RS'')<nowiki>-2-{4-[2-Hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide</nowiki>
| image = Atenolol.svg
| width = 200
| image2 = Atenolol_3d_structure.png
| width2 = 200
| imagename = 1 : 1 mixture (racemate)
| drug_name = Atenolol

<!--Clinical data-->
| tradename = Tenormin
| Drugs.com = {{drugs.com|monograph|atenolol}}
| MedlinePlus = a684031
| licence_US = Atenolol
| pregnancy_AU = C
| pregnancy_US = D
| legal_status = Rx-only
| routes_of_administration = Oral or [[Intravenous|IV]]

<!--Pharmacokinetic data-->
| bioavailability = 40-50%
| protein_bound = 6-16%
| metabolism = [[Liver|Hepatic]] <10%
| elimination_half-life = 6-7 hours
| excretion = [[Kidney|Renal]]<br />[[Mammary_gland|Lactic]] (In lactiferous females)

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 29122-68-7
| ATC_prefix = C07
| ATC_suffix = AB03
| PubChem = 2249
| IUPHAR_ligand = 548
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00335
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2162
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 50VV3VW0TI
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00235
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 2904
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 24

<!--Chemical data-->
 | C=14 | H=22 | N=2 | O=3 
| molecular_weight = 266.336 g/mol
| smiles = O=C(N)Cc1ccc(OCC(O)CNC(C)C)cc1
| InChI = 1/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
| InChIKey = METKIMKYRPQLGS-UHFFFAOYAT
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = METKIMKYRPQLGS-UHFFFAOYSA-N
}}

'''阿替洛尔'''（{{lang-en|Atenolol}}）是一种选择性的{{le|肾上腺素受体β1|beta-1 receptor|β<sub>1</sub>肾上腺素受体}}[[受体拮抗剂|拮抗剂]]，[[β-受体阻滞药|β-受体阻滞药]]的一种，用于治疗[[心血管疾病|心血管疾病]]。在1976年，阿替洛尔被研发出来替代[[普萘洛尔|普萘洛尔]]作为治疗[[高血壓|高血壓]]的药物，能降低心脏的活性。但与普萘洛尔不同，阿替洛尔不经过[[血脑屏障|血脑屏障]]，从而避免各种对[[中樞神經系統|中樞神經系統]]的副作用<ref name="BBB">{{cite journal |author=Agon P, Goethals P, Van Haver D, Kaufman JM |title=Permeability of the blood–brain barrier for atenolol studied by positron emission tomography |journal=J. Pharm. Pharmacol. |volume=43 |issue=8 |pages=597–600 |date=August 1991 |pmid=1681079 |doi= 10.1111/j.2042-7158.1991.tb03545.x|url= }}</ref>。

==註釋==
{{Reflist|30em}}

==參考文獻==
{{refbegin}}
*K.Viveksarathi et al.,Formulation Development and In-Vitro Evaluation of Gastroretentive Floating tablets of Atenolol. Journal of Pharmaceutical Sciences & Research;2011, Vol.3(12),p1632. http://www.jpsr.pharmainfo.in/Documents/Volumes/vol3Issue12/jpsr%2003111207.pdf
{{refend}}

==外部链接==
* {{cite news | url = http://www.dailymail.co.uk/health/article-403973/Beta-blockers-increase-diabetes-risk-50-cent.html | title = Beta-blockers 'increase diabetes risk by 50 per cent' | publisher = Daily Mail | location=London | first=Jenny | last=Hope | date=6 September 2006}}

{{Β受体阻滞剂}}
{{Adrenergics}}
{{阿斯利康制药}}

[[Category:醇|Category:醇]]
[[Category:酰胺|Category:酰胺]]
[[Category:阿斯利康制药|Category:阿斯利康制药]]
[[Category:Β阻滞药|Category:Β阻滞药]]
[[Category:芳香醚|Category:芳香醚]]
[[Category:1976年面世的產品|Category:1976年面世的產品]]